
SENSITIVITY OF HUMAN TUMORS WITH VARIOUS EXPRESSION OF RECAF RECEPTOR TO AFP-CONTAINING COMPLEX OF AIMPILA IN VIVO
Author(s) -
G. P. Smirnova,
С А Цуркан,
Yu. A. Borisova,
J. R Tcherkassova,
В. И. Романенко,
М С Калишьян,
H. M. Treshalina
Publication year - 2017
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2017-22-5-288-291
Subject(s) - in vivo , apoptosis , receptor , transplantation , liver cancer , cancer , colorectal cancer , medicine , cancer research , in vitro , chemistry , biology , biochemistry , microbiology and biotechnology
Experimental studies were carried out with non-covalent complex AIMPILA targeting on AFP receptors (ReCAF). The human subcutaneous xenografts were used with different ReCAF containing transplanted to immunodeficient mice Balb/c nude: colon cancer SW620/ReCAF +, liver cancer HepG2/ReCAF + + and breast cancer T47D/ReCAF + + +. IMPILA was administrated per os under beginning on 4th day after tumor transplantation daily for 5 or 10 days in the total doses of 0.5-2.0 mg/kg or 1.0-4.0 mg/kg, accordingly. The inhibiting effect (T/C < 42%) of AIMPILA was shown to increase in dependence on ReCAF containing on tumor cells: T/C = 70% (SW620/ReCAF +); T/C = 51% (HepG2/ReCAF + +) and T/C = 22% (T47D/ReCAF+++). On the more sensitive model in a series of experiences 10-times course for the treatment with the total dose of 4.0 mg/kg was detected and revealed to T/C = 15-37% (p < 0.05). In the pathomorphological investigation of the T47D/ReCAF+++ tumor there was verified the death of the majority of tumor cells under the treatment of AIMPILA via the apoptosis pathway.